Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q1 FY23 results · Apr–Jun 2022
Panacea Biotec reported revenue from operations of ₹110.70 crore (down 16.4% from Q1 FY22) and net loss of ₹56.14 crore for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 110.70 | 132.45 | −16.4% | 140.73 | −21.3% |
| Other income | 12.21 | 3.23 | +278.0% | 4.05 | +201.5% |
| Total income | 122.91 | 135.68 | −9.4% | 144.78 | −15.1% |
| Profit before tax | (51.16) | (57.27) | Loss narrowed | 1,608.26 | Turned loss |
| Net profit for the period | (56.14) | (57.35) | Loss narrowed | 1,237.47 | Turned loss |
| EPS, basic (₹) | (9.17) | (9.36) | Loss narrowed | 202.03 | Turned loss |
| Net margin (%) | -50.7 | -43.3 | 879.3 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 61.34 | 36.26 | +69.2% | 41.50 | +47.8% |
| Other income | 6.53 | 4.15 | +57.3% | 2.57 | +154.1% |
| Total income | 67.87 | 40.41 | +68.0% | 44.07 | +54.0% |
| Profit before tax | (74.24) | (23.47) | Loss widened | (25.31) | Loss widened |
| Net profit for the period | (74.24) | (23.47) | Loss widened | (25.31) | Loss widened |
| EPS, basic (₹) | (12.12) | (3.83) | Loss widened | (4.13) | Loss widened |
| Net margin (%) | -121.0 | -64.7 | -61.0 |
Consolidated
- Filed with BSE
- 24 Aug 2022, 12:48 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Aug 2022, 12:48 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE